CT-388 is a "biased" dual GLP-1 and GIP receptor agonist/modulator with minimal to no beta-arrestin coupling at either receptor and is designed to be administered as once weekly subcutaneous injection. From Wikipedia
The collaboration aims to co-develop Zealand's petrelintide and combine it with Roche's CT-388 to address the growing weight-loss drug market.
